Recurrent Fallopian Tube Carcinosarcoma
2 clinical trials · Condition
◉ Watch Recurrent Fallopian Tube Carcinosarcoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751) | National Cancer Institute (NCI) | 2025-10-31 |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (NCT06483048) | Mayo Clinic | 2024-09-20 |
Track Recurrent Fallopian Tube Carcinosarcoma automatically
Every clearance here is in the API, with alerts when new ones post.